title: PPARalpha ligands cause lymphocyte depletion and cell cycle block and this is associated with augmented TRB3 and reduced Cyclin B1 expression.
abstract: PPARalpha ligands are medications used clinically to prevent cardiovascular events, however studies have shown that these agents are also anti-inflammatory. Our previous studies have shown that PPARalpha ligands induce lymphocyte depletion. PPARalpha ligands also potently upregulate TRB3, a protein that has been associated with cell cycle arrest. Therefore the following studies were undertaken to determine the mechanisms associated with lymphocyte depletion. Our studies demonstrate that WY14,643, a PPARalpha ligand, decreases the amount of lymphocytes recovered after stimulation and reduces cellular divisions. Cells treated with WY14,643 also accumulate in the G2/S phase of the cell cycle. TRB3 has been shown to inhibit the phosphorylation of AKT/Protein Kinase B, and reduced activation of AKT has been associated with decreased cellular divisions and survival. However in lymphocytes, TRB3 did not reduce the phosphorylation of AKT, and WY14,643 treatment was associated with enhanced activation of AKT. Drosophila tribbles (TRB3 homolog) causes G2 arrest by decreasing the expression of a Cdc25c homolog. Lymphocytes stimulated and treated with WY14,643 have reduced expression of Cdc25c, however this is not associated with enhanced expression of phosphorylated-Cdc2 which induces G2 arrest. Instead we observed that WY14,643 consistently reduces the protein and mRNA expression of Cyclin B1. Moreover, TRB3 inhibits activation of a Cyclin B1 promoter construct. In summary, we propose that PPARalpha ligands may reduce cellular number by augmenting TRB3 expression, which in turn induces cell cycle arrest by reducing the expression of Cyclin B1. Reduced cellular divisions and cell cycle arrest may be responsible for some of the immunomodulatory effects of these agents that have been consistently observed in human trials.
authors.affiliation: Research Service and Division of Nephrology-Hypertension, Veterans Affairs San Diego Healthcare System, Veterans Medical Research Foundation, San Diego, CA 92161, USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Morse
authors.forename: Erin
authors.initials: E
authors.lastname: Selim
authors.forename: Robyn
authors.initials: R
authors.lastname: Cunard
mesh_terms: D000818:Animals; D018797:Cell Cycle Proteins / Q000276:immunology* / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D019926:Cyclin B / Q000096:biosynthesis / Q000276:immunology; D056744:Cyclin B1; D016195:G2 Phase / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D008024:Ligands; D008212:Lymphocyte Depletion; D008214:Lymphocytes / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D047493:PPAR alpha / Q000819:agonists* / Q000276:immunology* / Q000378:metabolism; D020025:Peroxisome Proliferators / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects / Q000276:immunology; D011401:Promoter Regions, Genetic / Q000276:immunology; D051057:Proto-Oncogene Proteins c-akt / Q000096:biosynthesis / Q000276:immunology; D011743:Pyrimidines / Q000494:pharmacology*; D016196:S Phase / Q000187:drug effects* / Q000276:immunology; D015854:Up-Regulation / Q000187:drug effects* / Q000276:immunology; D020687:cdc25 Phosphatases / Q000276:immunology
chemical_list: C534699:CCNB1 protein, human; C534700:Ccnb1 protein, mouse; D018797:Cell Cycle Proteins; D019926:Cyclin B; D056744:Cyclin B1; D008024:Ligands; D047493:PPAR alpha; D020025:Peroxisome Proliferators; D011743:Pyrimidines; C474830:TRB3 protein, mouse; C006253:pirinixic acid; D051057:Proto-Oncogene Proteins c-akt; C517010:Cdc25c protein, mouse; D020687:cdc25 Phosphatases